Alliqua, a developer of proprietary drug delivery and liver health technologies, has completed its initial study for the transdermal pain patch project.
In the comparative dissolution study, the Alliqua patch demonstrated a favorable profile when compared to the market leading product for treatment of PHN pain.
Based on the positive results, Alliqua will proceed to the next developmental stage, including in vitro testing.
Alliqua president and director Richard Rosenblum said the successful outcome of the study validates the progress Alliqua has made in creating a specialized transdermal pain patch based on their proprietary hydrogel technology.
"With additional products currently in development, this is the first of many important steps towards our goal of becoming a leading specialty pharmaceutical company," Rosenblum said.
Alliqua intends to continue pursuing a generic version of an existing pain management patch for the treatment of postherpetic neuralgia (PHN).